PRODUCT DEVELOPMENT PROTOCOL REENGINEERING PROPOSAL SUGGESTS "REAL-TIME" REVIEWS OF CHANGES DURING STUDIES; PMA REENGINEERING TEAM TO BE FORMED
This article was originally published in The Gray Sheet
Executive SummaryFDA expects "real-time" reviews during the product development protocol process will help eliminate obstacles that prevented effective use of the PDP approach in the past.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.